Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) ; volume:21 ; number:1 ; day:18 ; month:10 ; year:2021 ; pages:1-6 ; date:12.2021
BMC cancer ; 21, Heft 1 (18.10.2021), 1-6, 12.2021
- Urheber
-
Miyawaki, Taichi
Kenmotsu, Hirotsugu
Harada, Hideyuki
Ohde, Yasuhisa
Chiba, Yasutaka
Haratani, Koji
Okimoto, Tamio
Sakamoto, Tomohiro
Wakuda, Kazushige
Ito, Kentaro
Uemura, Takehiro
Sakata, Shinya
Kogure, Yoshihito
Nishimura, Yasumasa
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08851-z
- URN
-
urn:nbn:de:101:1-2022011121303635790797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miyawaki, Taichi
- Kenmotsu, Hirotsugu
- Harada, Hideyuki
- Ohde, Yasuhisa
- Chiba, Yasutaka
- Haratani, Koji
- Okimoto, Tamio
- Sakamoto, Tomohiro
- Wakuda, Kazushige
- Ito, Kentaro
- Uemura, Takehiro
- Sakata, Shinya
- Kogure, Yoshihito
- Nishimura, Yasumasa
- Nakagawa, Kazuhiko
- Yamamoto, Nobuyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Is Further Evaluation of Areas with Faint MDP Uptake Needed in Individuals with Oligo-Metastatic Prostatic Adenocarcinoma?
EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligo-metastatic disease: an observational prospective multicentric study
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study
Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study
Oligometastatic Prostate Cancer
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Is Further Evaluation of Areas with Faint MDP Uptake Needed in Individuals with Oligo-Metastatic Prostatic Adenocarcinoma?
EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligo-metastatic disease: an observational prospective multicentric study
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study
Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study
Oligometastatic Prostate Cancer
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Is Further Evaluation of Areas with Faint MDP Uptake Needed in Individuals with Oligo-Metastatic Prostatic Adenocarcinoma?
EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligo-metastatic disease: an observational prospective multicentric study
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study
Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study
Oligometastatic Prostate Cancer
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study